Wall Street kicked off the trading week on a sour note, with all three major indices recording huge losses, amid lingering investor concerns about the fate of artificial intelligence buildout.
The Nasdaq fell the most, slashing 2.49 percent, followed by the S&P 500 declining 1.92 percent. The Dow Jones tumbled 1.41 percent.
Meanwhile, 10 stocks led the session’s fall, slashing more than 9 to 16 percent of their value. In this article, we identified their names and detailed the reasons behind their drop.
To come up with the list, we considered the stocks with more than $1 billion in market capitalization and at least 5 million shares in trading volume.

The New York Stock Exchange building. Photo by Дмитрий Трепольский on Pexels
10. Intuitive Machines Inc. (NASDAQ:LUNR)
Intuitive Machines saw its share price decline by 9.77 percent on Monday to close at $11.73 as investors resorted to profit-taking following last week’s climb to the $13 territory.
This followed its earnings performance in the third quarter of the year and the successful bagging of a new contract from the National Aeronautics and Space Administration (NASA) under its new $10 billion commercial payload services 2, designed to support more capable cargo missions at greater frequency, advancing Artemis and Moon Base infrastructure requirements, including transportation, mobility, power, habitats, and logistics.
Its selection followed its successful CLPS task orders, including two this year.
In March, NASA awarded Intuitive Machines Inc. (NASDAQ:LUNR) a $180.4 million contract for its larger cargo-class Nova-D lunar lander, followed in June by an award valued at up to $148.3 million for a production line-qualified Nova-C lander.
In other news, Intuitive Machines Inc. slashed its net losses attributable to shareholders in the second quarter of the year by 40 percent to $4.19 million from $7 million in the same period last year.
Total revenues soared by 418 percent to $269.3 million from $52.4 million year-on-year, primarily driven by product revenues of $215 million and a 6 percent jump in service revenues at $54 million.
9. Absci Corp. (NASDAQ:ABSI)
Absci Corp. dropped for a third straight day on Monday, slashing 11.54 percent to end at $7.48 apiece after receiving a price target cut for its stock.
In a market note, Guggenheim Securities reduced its price target to $14 from $15 previously, while maintaining a buy recommendation, after technically adjusting its model to a fully diluted share count in its discounted cash flow analysis. It said that the stock may be particularly volatile into and around the December data.
The target cut followed Absci Corp.’s (NASDAQ:ABSI) earnings performance in the third quarter of the year, where it registered a 16 percent higher net loss of $33.3 million versus $28.7 million in the same period last year.
Absci Corp. remains a pre-revenue company, having no commercial sales yet, although it earns from partner programs.
Partner program revenues during the period stood at $304,000 versus $378,000 year-on-year.
Last week, the company named Gerry Muhle as its new chief commercial officer to lead commercialization of prescription medicines and build consumer brands to advance ABS-201 and the company’s broader pipeline.
Muhle brings more than 25 years of commercial leadership experience, having led multiple successful product launches across prescription medicines, aesthetics, and consumer skincare, and held full P&L responsibility for major businesses at his previous companies.
Prior to Absci Corp., Muhle served as Senior Vice President and Head of Global Product Strategy for Galderma, where he led global commercial and product strategy across the company’s entire portfolio, spanning all three businesses: therapeutic dermatology, injectable aesthetics, and dermatological skincare.
8. Strive Inc. (NASDAQ:ASST)
Strive Inc. dropped its share price by 11.94 percent on Monday to finish at $18.81 apiece as investors weighed its move to acquire more Bitcoins for $17.5 million.
In a regulatory filing on the same day, the finance and asset management company said that it boosted its Bitcoin ownership by 251 to a total of 43,404 following a series of acquisitions between November 7 and 13.
This followed another one earlier this month, where it scooped up 124 Bitcoins for around $10 million.
Meanwhile, prices of Bitcoin were down by 0.02 percent on Monday to $65,298 apiece.
In other news, Strive Inc. (NASDAQ:ASST) reported a strong earnings performance in the third quarter of the year, having swung to a net income attributable to shareholders of $474.8 million from a $192.3 million net loss in the same period last year. Total revenues increased by 957 percent to $2.696 million from $255,000 year-on-year, thanks to a 534 percent jump in advisory fees coupled with $1.133 million in revenues from medical devices.
“Strive has continued to successfully execute on its treasury management strategy, delivering a strong Bitcoin yield year to date in 2026, which I believe is the primary driver of our common equity’s outperformance relative to Bitcoin so far this year,” Strive Inc. Chairman and CEO Matthew Cole said.
“We believe Strive has never been in a better position to generate long-term returns in excess of Bitcoin for our common equity shareholders,” he noted.
7. Navitas Semiconductor Corp. (NASDAQ:NVTS)
Navitas Semiconductor extended its losing streak to a third consecutive day on Monday, shedding 11.96 percent to finish at $7.88 amid lingering concerns over the trajectory of AI infrastructure buildout.
The stock mirrored an overall market pessimism led by the tech-heavy Nasdaq, declining 2.49 percent, while the S&P 500 decreased 1.92 percent and the Dow Jones slashed 1.41 percent, weighed down by uncertainties surrounding Nvidia Corp.
This followed reports on Monday that Nvidia was not considering the return of Jensen Huang as its chief executive despite growing calls from employees, Elon Musk, and even President Donald Trump.
It can be recalled that Huang’s immediate departure last week sent shockwaves across broader markets given its dominance in the artificial intelligence industry. Under Huang’s leadership, the company’s AI strategy and product roadmap helped establish it as the bellwether of the global AI infrastructure buildout.
In other developments, Navitas Semiconductor Corp. (NASDAQ:NVTS) last week filed a lawsuit against Renesas Electronics Corporation over six counts of patent infringement.
The listed firm previously filed a separate lawsuit against Renesas on August 10, 2026, alleging that their major GaN product lines, including SuperGaN power semiconductors, infringe patents within Navitas’ industry-leading GaN patent portfolio.
The ongoing litigation, Navitas Semiconductor Corp., has not deterred Renesas from its alleged infringement, having launched its 650 V SuperGaN GaN FET on September 30.
6. Trump Media & Technology Group Corp. (NASDAQ:DJT)
Trump Media extended losses to a third consecutive day on Monday, losing 12.07 percent to finish at $4.08 apiece, as investor sentiment was dampened by the potential dilution of its $1 billion convertible notes nearing their redemption date.
This followed a regulatory filing indicating that holders of convertible notes due 2028 could demand to be repaid in cash or convert their notes to shares of Trump Media & Technology Group Corp. on November 30, 2026.
The notes can be converted into shares at a price of $34.72 apiece, or at a 751 percent premium over its closing price on Monday.
The company said in its latest quarterly filing that it would fund any repayment from a combination of cash, asset sales, revenues, new fundraising activities, or through a new credit facility.
In other developments, Trump Media & Technology Group Corp. reported a stellar earnings performance in the third quarter of the year, ending with a $409.7 million net income, reversing a $54.8 million net loss in the same period last year, reflecting non-cash items, including net realized and unrealized gains on digital assets, digital assets pledged, and equity securities, partially offset by realized and unrealized loss on derivatives, accreted interest expense, stock-based compensation, and investment expenses resulting in $12.3 million of Adjusted EBITDA loss.
Revenues stood at $3 million, up 205 percent from $972,900 year-on-year, primarily driven by $1.8 million of subscription growth in the media segment from Truth API, its first data licensing product, which was launched on August 1, 2026, Truth+, and management fees in TruthFi ETF offerings.
5. AST SpaceMobile Inc. (NASDAQ:ASTS)
AST SpaceMobile slashed its share price by 12.33 percent on Monday—a third straight day—amid lingering investor concerns over its launch delays, while mirroring the broader market’s decline.
In its latest earnings call, it can be recalled that AST SpaceMobile Inc. (NASDAQ:ASTS) pushed its target to launch 45 satellites to mid-2027 from its original timeline of early next year amid delays in the shipments of BlueBird satellites.
BlueBirds 14 to 16 have been shipped to Cape Canaveral in September 2026 and are only awaiting SpaceX’s launch date confirmation, while BlueBirds 17 to 19 are expected to ship by the end of the month for a launch aboard Blue Origin in early the first quarter of 2027.
BlueBirds 20 to 25 are targeted for shipments in December and January for expected DPAS-rated dual-use launches in the first quarter of the year.
In other news, AST SpaceMobile Inc. widened its net loss attributable to shareholders in the third quarter of the year by 7.7 percent to $132.38 million from $122.87 million in the same period last year.
Total revenues, however, soared by 188 percent to $42.32 million from $14.7 million year-on-year, thanks to gateway deliveries and US government milestones.
4. USA Rare Earth Inc. (NASDAQ:USAR)
USA Rare Earth dropped its share price by 12.62 percent on Monday to end at $7.13 apiece after receiving a rating downgrade from William Blair over feedstock shortages.
In a market note, the investment firm lowered its stock rating for USA Rare Earth Inc. (NASDAQ:USAR) to market perform from outperform previously on the belief that it is likely to face near-term challenges, including recent feedstock shortages that are slowing rare earth magnet production.
Additionally, William Blair underscored USA Rare Earth Inc.’s short track record as a publicly listed company and warned against investing in a company that has yet to demonstrate the ability to ramp up production to its full potential.
Despite the downgrade, USA Rare Earth Inc. still holds a strong buy rating across six analysts covering the stock, five of which recommended buying its shares, while one said to hold.
This month alone, Northland Securities, Roth MKM, and Cantor Fitzgerald all reiterated their buy recommendations on the mining firm’s stock, albeit lowering their price targets to a range of $20 to $30 from $30 to 45 prior.
In other news, USA Rare Earth Inc. announced that the start of shipping of mixed rare earth carbonate to US SIIE, LLC—a special purpose vehicle funded by the US government. It also began receiving payments this month.
The shipment forms part of a 15-year take-or-pay offtake agreement providing for the sale of products derived from Serra Verde’s Phase 1 production to US SIIE, including neodymium (Nd), praseodymium (Pr), dysprosium (Dy) and terbium (Tb).
3. GDS Holdings Ltd. (NASDAQ:GDS)
GDS Holdings Ltd. (NASDAQ:GDS) fell by 14.69 percent on Monday to finish at $16.90, mimicking a broader decline in the US markets, dampened by uncertainties surrounding Nvidia Corp. and its impact on the broader artificial intelligence sector.
Considered the bellwether of the global AI infrastructure buildout, Nvidia’s fall to record lows last week spilled over to related technology stocks amid concerns about the industry’s growth trajectory.
Investors also positioned portfolios ahead of Nvidia Corp.’s earnings release after market close on Tuesday, November 17, which is expected to shed light on its leadership composition following Jensen Huang’s resignation, alongside its updated outlook over the short-term period.
For its part, GDS Holdings Ltd. is set to announce the results of its earnings performance for the third quarter of the year before market open on November 25. A conference call will be held to elaborate on the results.
In its last earnings call, GDS Holdings Ltd. guided a full-year total revenue outlook of RMB 12.7 billion to RMB 13 billion, or an upgrade from the RMB 12.4 billion to RMB 12.9 billion expected in the first quarter of the year.
2. Icahn Enterprises LP (NASDAQ:IEP)
Icahn Enterprises fell by 15.09 percent on Monday to close at $3.6 apiece, as investors disposed of its shares following the ex-date for its next dividend payment.
It can be recalled that the company’s board of directors approved the distribution of $0.50 in dividends to all depositary unit holders of November 16 record, payable on December 23. The dividends form part of Icahn Enterprises LP’s (NASDAQ:IEP) quarterly dividends.
The distribution announcement followed Icahn Enterprises LP’s earnings results in the third quarter of the year, where it swung to an attributable net loss of $225 million from a $287 million net income in the same period last year amid refining hedges in the investment funds attributable to the company.
Revenues, on the other hand, increased by 16 percent to $3.17 billion from $2.7 billion year-on-year, with net sales contributing to the bulk at $3.549 billion, or 53 percent higher than the $2.3 billion year-on-year.
However, the higher net sales were offset by losses from investment activities, at $779 million versus $48 million in the same comparable period.
Adjusted EBITDA attributable to the company ended at a loss of $214 million, as compared with a $75 million adjusted EBITDA year-on-year.
1. Summit Therapeutics Inc. (NASDAQ:SMMT)
Summit Therapeutics fell for a 5th straight day on Monday to touch a new 52-week low after the Food and Drug Administration (FDA) thumbed down its Biologics License Application (BLA) for its lung cancer treatment candidate, Ivonescimab, amid the lack of substantial evidence in overall survival data.
In intraday trading, the stock nosedived to a record low of $11.54 before paring losses to end the day down by 16.47 percent at $11.82 apiece.
Summit Therapeutics Inc. (NASDAQ:SMMT) said that the FDA rejected its BLA after determining that substantial evidence of effectiveness was not established amid the absence of a statistically significant improvement in enrolled patients’ overall survival.
Additionally, the FDA indicated that data on progression-free survival (PFS) without any improvement in overall survival do not support a positive benefit-risk profile.
The BLA was based on Summit Therapeutics Inc.’s data from its double-blind Phase 3 clinical trial, which aimed to study Ivonescimab in combination with chemotherapy, where PFS—its primary endpoint—was met.
The study found that Ivonescimab combined with chemotherapy was well-tolerated with no new safety signals and comparable rates of discontinuation and death.
However, 16 patients in the Ivonescimab group and 11 patients in the placebo group discontinued due to adverse effects.
Nine patients died, including four from the Ivonescimab plus chemotherapy arm group, and five in the chemotherapy alone.
“We are disappointed for patients and their families awaiting additional treatment options in this setting,” Chairman and CEO Robert Duggan said.
“With five positive Phase 3 studies between Summit and Akeso, nothing changes with respect to our ever-growing belief in the opportunity for Ivonescimab and our determination to advance Ivonescimab’s development. Our mission remains to improve outcomes for patients facing significant unmet needs, which is work worth doing, and we will continue through our expansive clinical development program,” he noted.
READ NEXT: Forget Nvidia: 10 Stocks Wall Street is Betting on Right Now and Buy Alert: 10 Stocks Analysts Upgraded on Friday





